multiple hepatocellar carcinomas
Conditions
Interventions
Epirubicin-TACE
Cisplatin-TACE
Sponsors
Department of Surgery, Graduate School of Medicine Kyoto Uinversity
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1)Patients with HCC that are histologically or clinically confirmed 2)Patients with multiple HCCs that are diagnosed as stage2-4a and cannot be selected for surgical resection or local ablation 3)Patients without severe tumor thrombosis in the portal vein, hepatic vein and the bile duct 4)Patients under Child-Pugh A or B 5)Patients under PS 0 or 1 6)Patients who fulfill all of the selected criteria below 1.WBC>=3000/mm3 2.Plt>=5x10^4/mm3 3.Hb>=8.0g/dl 4.T-Bil=<3.0mg/dl 5.ALB=<2.8g/dl 6.CRE=<1.2mg/dl 7)Patients who are 20 years and older and who are autonomous independent adults
Exclusion criteria
Exclusion criteria: 1)Patients with another active cancer 2)Patients with extrahepatic metastasis 3)Patients with prior surgical reconstruction of the biliary tract or prior endoscopic treatment of ampulla of vater 4)Patients with clinically significant refractory ascites or pleural effusion 5)Patients with hepatic encephalopathy 6)Patients with severe co-morbidity such as cardiac failure and renal failure 7) Patients who have taken doses of chemotherapeutic agents with cardiac toxicity exceeding a set threshold. 8)Patients with a medical history of severe hypersensitivity 9)Patients who are pregnant, lactating or are suspected to be pregnant. 10)Patients who are concluded to be inappropriate to participate in this study by their physicians
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Response rate(based on EASL criteria) | — |
Secondary
| Measure | Time frame |
|---|---|
| Overall survival Progression free survival Response rate(based on the General Rules for the Clinical and Pathological Study of Primary Liver Cancer) Safety | — |
Countries
Japan
Contacts
Public ContactHatano Etsuro
Graduate School of Medicine Kyoto Uinversity Department of Surgery
Outcome results
None listed